Equities research analysts at Berenberg Bank initiated coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a report released on Wednesday, March 27th, The Fly reports. The firm set a “buy” rating on the stock.
Several other equities research analysts also recently commented on the stock. Raymond James assumed coverage on shares of Gritstone Oncology in a research note on Thursday, March 14th. They issued an “outperform” rating and a $20.00 target price on the stock. HC Wainwright assumed coverage on shares of Gritstone Oncology in a research note on Thursday, March 7th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, BTIG Research boosted their target price on shares of Gritstone Oncology to $31.00 and gave the company a “buy” rating in a research note on Tuesday, December 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Gritstone Oncology currently has an average rating of “Buy” and an average target price of $22.20.
Shares of NASDAQ:GRTS traded down $0.16 on Wednesday, hitting $13.74. The stock had a trading volume of 42,079 shares, compared to its average volume of 167,561. Gritstone Oncology has a twelve month low of $9.66 and a twelve month high of $32.90. The company has a market capitalization of $401.13 million and a PE ratio of -1.89.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Citigroup Inc. acquired a new position in Gritstone Oncology during the 4th quarter worth about $28,000. Strs Ohio acquired a new position in Gritstone Oncology during the 4th quarter worth about $29,000. American International Group Inc. acquired a new position in Gritstone Oncology during the 4th quarter worth about $70,000. Riverhead Capital Management LLC acquired a new position in Gritstone Oncology during the 3rd quarter worth about $141,000. Finally, Point72 Asset Management L.P. acquired a new position in Gritstone Oncology during the 3rd quarter worth about $142,000. Institutional investors and hedge funds own 58.96% of the company’s stock.
Gritstone Oncology Company Profile
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Read More: SEC Filing
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.